FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890760513> ?p ?o ?g. }

• W2890760513 abstract "Most patients with advanced prostate cancer develop bone metastases, which often result in painful and debilitating skeletal-related events. Inhibitors of bone resorption, such as bisphosphonates and denosumab, can each reduce the incidence of skeletal-related events and delay the progression of bone pain. However, these agents are associated with an increased risk of hypocalcaemia, which, although often mild and transient, can be serious and life-threatening. Here we provide practical advice on managing the risk of hypocalcaemia in patients with advanced prostate cancer who are receiving treatment with bone resorption inhibitors. Relevant references for this review were identified through searches of PubMed with the search terms 'prostate cancer', 'bone-targeted agents', 'anti-resorptive agents', 'bisphosphonates', 'zoledronic acid', 'denosumab', 'hypocalcaemia', and 'hypocalcemia'. Additional references were suggested by the authors.Among patients with advanced cancer receiving a bisphosphonate or denosumab, hypocalcaemia occurs most frequently in those with prostate cancer, although it can occur in patients with any tumour type. Consistent with its greater ability to inhibit bone resorption, denosumab has shown superiority in the prevention of skeletal-related events in patients with bone metastases from solid tumours. Consequently, denosumab is more likely to induce hypocalcaemia than the bisphosphonates. Likewise, various bisphosphonates have differing potencies for the inhibition of bone resorption, and thus the risk of hypocalcaemia varies between different bisphosphonates. Other risk factors for the development of hypocalcaemia include the presence of osteoblastic metastases, vitamin D deficiency, and renal insufficiency. Hypocalcaemia can lead to treatment interruption, but it is both preventable and manageable. Serum calcium concentrations should be measured, and any pre-existing hypocalcaemia should be corrected, before starting treatment with inhibitors of bone resorption. Once treatment has started, concomitant administration of calcium and vitamin D supplements is essential. Calcium concentrations should be monitored during treatment with bisphosphonates or denosumab, particularly in patients at high risk of hypocalcaemia. If hypocalcaemia is diagnosed, patients should receive treatment with calcium and vitamin D.With preventative strategies and treatment, patients with prostate cancer who are at risk of, or who develop, hypocalcaemia should be able to continue to benefit from treatment with bisphosphonates or denosumab." @default.
• W2890760513 created "2018-09-27" @default.
• W2890760513 creator A5000145349 @default.
• W2890760513 creator A5020692060 @default.
• W2890760513 creator A5025804381 @default.
• W2890760513 creator A5053293171 @default.
• W2890760513 date "2018-09-20" @default.
• W2890760513 modified "2023-10-17" @default.
• W2890760513 title "Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion" @default.
• W2890760513 cites W1483901766 @default.
• W2890760513 cites W1517224081 @default.
• W2890760513 cites W1665793155 @default.
• W2890760513 cites W1965228094 @default.
• W2890760513 cites W1966652024 @default.
• W2890760513 cites W1985645291 @default.
• W2890760513 cites W1997823019 @default.
• W2890760513 cites W2004143865 @default.
• W2890760513 cites W2006825597 @default.
• W2890760513 cites W2006833762 @default.
• W2890760513 cites W2013255538 @default.
• W2890760513 cites W2015448616 @default.
• W2890760513 cites W2017845136 @default.
• W2890760513 cites W2027283399 @default.
• W2890760513 cites W2033273914 @default.
• W2890760513 cites W2034660036 @default.
• W2890760513 cites W2037738101 @default.
• W2890760513 cites W2039750668 @default.
• W2890760513 cites W2045662372 @default.
• W2890760513 cites W2048771841 @default.
• W2890760513 cites W2084283324 @default.
• W2890760513 cites W2098256087 @default.
• W2890760513 cites W2099724875 @default.
• W2890760513 cites W2104923745 @default.
• W2890760513 cites W2106744421 @default.
• W2890760513 cites W2112950162 @default.
• W2890760513 cites W2118814475 @default.
• W2890760513 cites W2123055653 @default.
• W2890760513 cites W2124070987 @default.
• W2890760513 cites W2127999709 @default.
• W2890760513 cites W2133838604 @default.
• W2890760513 cites W2139860898 @default.
• W2890760513 cites W2141454098 @default.
• W2890760513 cites W2144402273 @default.
• W2890760513 cites W2145405813 @default.
• W2890760513 cites W2149919990 @default.
• W2890760513 cites W2153059487 @default.
• W2890760513 cites W2161647960 @default.
• W2890760513 cites W2163753271 @default.
• W2890760513 cites W2182400851 @default.
• W2890760513 cites W2191300343 @default.
• W2890760513 cites W2317871507 @default.
• W2890760513 cites W2321847772 @default.
• W2890760513 cites W2407107838 @default.
• W2890760513 cites W2409104495 @default.
• W2890760513 cites W2419184441 @default.
• W2890760513 cites W2528282468 @default.
• W2890760513 cites W2539991828 @default.
• W2890760513 cites W2566831552 @default.
• W2890760513 cites W2575070901 @default.
• W2890760513 cites W2576656535 @default.
• W2890760513 cites W2604152167 @default.
• W2890760513 cites W2900477576 @default.
• W2890760513 cites W4205145397 @default.
• W2890760513 cites W4242024627 @default.
• W2890760513 doi "https://doi.org/10.1186/s12894-018-0393-9" @default.
• W2890760513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6148993" @default.
• W2890760513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30236112" @default.
• W2890760513 hasPublicationYear "2018" @default.
• W2890760513 type Work @default.
• W2890760513 sameAs 2890760513 @default.
• W2890760513 citedByCount "10" @default.
• W2890760513 countsByYear W28907605132019 @default.
• W2890760513 countsByYear W28907605132020 @default.
• W2890760513 countsByYear W28907605132021 @default.
• W2890760513 countsByYear W28907605132022 @default.
• W2890760513 countsByYear W28907605132023 @default.
• W2890760513 crossrefType "journal-article" @default.
• W2890760513 hasAuthorship W2890760513A5000145349 @default.
• W2890760513 hasAuthorship W2890760513A5020692060 @default.
• W2890760513 hasAuthorship W2890760513A5025804381 @default.
• W2890760513 hasAuthorship W2890760513A5053293171 @default.
• W2890760513 hasBestOaLocation W28907605131 @default.
• W2890760513 hasConcept C121608353 @default.
• W2890760513 hasConcept C124490489 @default.
• W2890760513 hasConcept C126322002 @default.
• W2890760513 hasConcept C126894567 @default.
• W2890760513 hasConcept C141071460 @default.
• W2890760513 hasConcept C143998085 @default.
• W2890760513 hasConcept C2776286101 @default.
• W2890760513 hasConcept C2776326535 @default.
• W2890760513 hasConcept C2776541429 @default.
• W2890760513 hasConcept C2777251235 @default.
• W2890760513 hasConcept C2778812048 @default.
• W2890760513 hasConcept C2780192828 @default.
• W2890760513 hasConcept C519063684 @default.
• W2890760513 hasConcept C673006 @default.
• W2890760513 hasConcept C71924100 @default.
• W2890760513 hasConceptScore W2890760513C121608353 @default.
• W2890760513 hasConceptScore W2890760513C124490489 @default.
• W2890760513 hasConceptScore W2890760513C126322002 @default.

• next